Fortunately, recent clinical trials of cancer immunotherapy have shown substantial survival benefits of antibodies against either programmed cell death-ligand 1 (PD-L1) or programmed cell death-1 (PD-1) in some types of cancer, including platinum-resistant or refractory EOC (3–5). Here, PDCD1 is linked to cancer.